sponsored
PatientsVille.com Logo

PatientsVille

Rosuvastatin Medical Research Studies

Up-to-date List of Rosuvastatin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Rosuvastatin Medical Research Studies

Rank Status Study
1 Not yet recruiting The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin
Condition: Healthy
Interventions: Drug: Rosuvastatin;   Drug: Rosuvastatin plus rifampin
Outcome Measures: Area-under-the-concentration curve (AUC) of Rosuvastatin;   Maximum plasma concentration (Cmax) of Rosuvastatin;   Time to concentration maximum (Tmax) of Rosuvastatin
2 Recruiting Relative Bioavailability Study of One Amlodipine 10mg Tablet and One Rosuvastatin 20mg Tablet to Two Fixed Dose Combinations of Amlodipine (10mg) and Rosuvastatin (20mg) in Healthy Subjects Under Fasting Conditions
Condition: Hypertension
Interventions: Drug: Amlodipine+Rosuvastatin;   Drug: GSK3074477 FDC - 1;   Drug: GSK3074477 FDC - 2
Outcome Measures: Plasma pharmacokinetics (PK) parameters of amlodipine and Rosuvastatin following single dose administration;   Additional PK parameters of amlodipine and Rosuvastatin following single dose administration;   Safety as assessed by adverse events;   Safety as assessed by vital signs;   Safety as assessed by clinical laboratory safety data;   Safety as assessed by Electrocardiogram (ECG) parameters
3 Not yet recruiting Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin
Condition: Hepatitis C
Interventions: Drug: Daclatasvir, Asunaprevir and BMS-791325 FDC;   Drug: BMS-791325;   Drug: Rosuvastatin
Outcome Measures: Maximum observed concentration (Cmax) of Rosuvastatin;   Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)) of Rosuvastatin;   Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of Rosuvastatin;   Time of maximum observed concentration (Tmax) of Rosuvastatin;   Half life (T-HALF) of Rosuvastatin;   Apparent total body clearance (CLT/F) of Rosuvastatin;   Maximum observed concentration (Cmax) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712;   Trough observed plasma concentration (predose) (Ctrough) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712;   Area under the concentration-time curve in one dosing interval [AUC(TAU)] of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712;   Time of maximum observed concentration (Tmax) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712;   Observed plasma concentration at 12 hours after dosing in a pharmacokinetic (PK) profile (C12) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712;   Safety measured by incidence of Adverse events (AEs), Serious adverse events (SAEs) and AEs leading to discontinuation;   Safety measured by results of vital sign measurements, Electrocardiogram (ECGs), physical examinations and clinical laboratory tests
4 Not yet recruiting Drug Interaction Study With Rosuvastatin
Condition: Immunosuppression For Disease
Interventions: Drug: BMS-986020;   Drug: Rosuvastatin
Outcome Measures: Maximum observed plasma concentration (Cmax) of Rosuvastatin with and without coadministered BMS-986020;   Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Rosuvastatin with and without coadministered BMS-986020;   Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of Rosuvastatin with and without coadministered BMS-986020;   Time of maximum observed plasma concentration (Tmax) of Rosuvastatin with and without coadministered BMS-986020;   Terminal plasma half-life (T-HALF) of Rosuvastatin with and without coadministered BMS-986020;   Apparent total body clearance (CLT/F) of Rosuvastatin with and without coadministered BMS-986020;   Incidence of Adverse Event (AEs), Serious Adverse Event (SAEs), deaths, and AEs leading to discontinuation;   Results of vital signs, ECGs, Physical Examination (PEs), and clinical lab result
5 Not yet recruiting Evaluating of Pharmacokinetic Profile of BCWP_C001 and Co-administration of Rosuvastatin and Metformin
Condition: Healthy
Interventions: Drug: Rosuvastatin and Metformin SR(Fed);   Drug: BCWP_C001(Fasted);   Drug: BCWP_C001(Fed)
Outcome Measures: Rosuvastatin, Metformin Cmax, AUClast;   N-desmethyl Rosuvastatin Cmax;   N-desmethyl Rosuvastatin AUClast;   N-desmethyl Rosuvastatin AUCinf;   Rosuvastatin, N-desmethyl Rosuvastatin, Metformin AUCinf;   Rosuvastatin, N-desmethyl Rosuvastatin, Metformin Tmax;   Rosuvastatin, N-desmethyl Rosuvastatin, Metformin t1/2;   Rosuvastatin, N-desmethyl Rosuvastatin, Metformin Vz/F;   Rosuvastatin, N-desmethyl Rosuvastatin, Metformin CL/F
6 Not yet recruiting Phase 1 Clinical Trial to Investigate the Effect on the Pharmacokinetics of YH14755 Compared to Co-administration of Rosuvastatin and Metformin SR in Healthy Volunteers
Condition: Healthy
Interventions: Drug: Rosuvastatin, Metformin, YH14755;   Drug: YH14755
Outcome Measures: AUClast of Rosuvastatin and metformin;   Cmax of Rosuvastatin and metformin;   Tmax of Rosuvastatin and metformin;   t1/2 of Rosuvastatin and metformin;   %AUC of Rosuvastatin and metformin;   AUCinf of Rosuvastatin and metformin
7 Recruiting Rosuvastatin to Decrease Residual Immune Activation in HIV Infection
Condition: HIV-1 Infection
Intervention: Drug: Rosuvastatin 20 mg/day
Outcome Measures: CD8 T cell activation;   Coexpress activation markers;   Rosuvastatin administration (on and off)on biomarkers activation;   Relationship between the levels of T-cell activation and of plasma HIV-RNA (ultrasensible measure);   CD4 T-cell count and on the CD4/CD8 T-cell ratio;   Lipids profiles on and off Rosuvastatine association;   Tolerance of Rosuvastatine
8 Not yet recruiting Rosuvastatin for Preventing Complications in Renal Ablation
Condition: Arterial Hypertension
Interventions: Drug: Rosuvastatin;   Drug: Placebo
Outcome Measures: Optical coherence tomography evidence of vascular injury induced by radiofrequency;   Post-procedural changes in renal function
9 Not yet recruiting Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe
Condition: Dyslipidemia
Interventions: Drug: NVP-1205;   Drug: Rosuvastatin+ezetimibe
Outcome Measures: AUClast;   AUCinf
10 Unknown  Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets
Conditions: Hypercholesterolemia;   HIV Infections
Interventions: Drug: Ezetimibe;   Drug: Rosuvastatin (standard care)
Outcome Measures: The primary endpoint is the difference in final value of serum apolipoprotein B between participants treated with Rosuvastatin versus participants treated with both Rosuvastatin and ezetimibe.;   Percent change in apolipoprotein B, percent and absolute change total cholesterol, LDL, HDL, triglycerides, apolipoprotein A1, apolipoproteinB/apoliporoteinA1 ratio and C-reactive protein;   Assessment of safety parameters, specifically incidence of complications as measured by an increase in AST &/or ALT ≥3-fold ULN & a CK ≥10-fold ULN
11 Recruiting Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity
Condition: Coronary Artery Disease
Interventions: Drug: Atorvastatin;   Drug: Rosuvastatin
Outcome Measures: Assessment of platelet reaction units;   Frequency of high platelet reactivity
12 Not yet recruiting Drug Interaction Statin
Condition: Acute Coronary Syndromes
Interventions: Drug: BMS-919373;   Drug: Rosuvastatin;   Drug: Atorvastatin
Outcome Measures: Maximum observed plasma concentration (Cmax) of Rosuvastatin and Atorvastatin;   Area under the plasma concentration-time curve from time zero to 72 hours (AUC(0-72)) of Rosuvastatin and Atorvastatin;   Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Rosuvastatin and Atorvastatin;   Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of Rosuvastatin and Atorvastatin;   Time of maximum observed plasma concentration (Tmax) of Rosuvastatin and Atorvastatin;   Terminal plasma half life (T-HALF) of Rosuvastatin and Atorvastatin;   Apparent total body clearance (CLT/F) of Rosuvastatin and Atorvastatin;   Safety based on results of physical examinations, vital sign measurements, ECGs, 24-hour telemetry, clinical laboratory tests, and physical measurements and will also include the incidence of AEs, SAEs and AEs leading to discontinuation
13 Recruiting Randomized Trial of Creatine-kinase Leak After Rosuvastatin At the Time of Percutaneous Coronary Intervention
Condition: Coronary Artery Disease
Intervention: Drug: Rosuvastatin
Outcome Measures: Periprocedural myocardial infarction (Myocardial enzymes arise);   Any creatine kinase elevation
14 Recruiting Evaluating a Pharmacokinetic Drug Interaction Between Amlodipine/Losartan and Rosuvastatin
Condition: Healthy
Interventions: Drug: amosartan;   Drug: Rosuvastatin;   Drug: amosartan and Rosuvastatin
Outcome Measures: Cmax;   AUClast;   tmax;   t1/2;   AUCinf
15 Unknown  Effect of Rosuvastatin on Endothelial Function
Conditions: HIV Infections;   Cardiovascular Disease
Intervention: Drug: Rosuvastatin
Outcome Measures: Change in flow mediated dilatation (FMD) of the brachial artery;   Change in HIV biomarkers of immune activation to include CD38 and CD69 expression on T cells and CD16 and CD69 expression on monocytes;   Change in mitochondrial-specific oxidative stress (mt-specific 8-oxo-dG) and oxidative phosphorylation (OXPHOS) protein/enzyme activity [Complex I and Complex IV] levels;   Change in glucose homeostasis and insulin resistance as assessed by oral glucose tolerance testing;   Change in total, HDL and LDL cholesterol and triglyceride levels;   Change in hsCRP
16 Not yet recruiting Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa)
Condition: Coronary Artery Disease
Interventions: Drug: Atorvastatin;   Drug: Rosuvastatin
Outcome Measures: Assessment of platelet reaction units;   Frequency of high platelet reactivity
17 Recruiting A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Hypercholesterolemia.
Condition: Hypercholesterolemia
Interventions: Drug: Rosuvastatin;   Drug: Crestor®
Outcome Measures: The primary efficacy variable will be defined as the percent mean change in LDL-C from baseline to 12 weeks.;   The secondary efficacy variable will be described as the change of plasma AGE, sRAGE, Gas6 and sAx1.
18 Unknown  Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)
Conditions: Hyperlipidemia;   Atherosclerosis
Intervention: Drug: Rosuvastatin (Crestor)
Outcome Measures: Change in the percentage of volume of lipid rich necrotic core (LRNC)using high-resolution MRI;   change in volume of wall and normalized wall index (NWI)
19 Unknown  Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume
Conditions: Hyperlipidemia;   Coronary Artery Disease
Intervention: Drug: Rosuvastatin
Outcome Measures: Change from baseline in coronary atherosclerosis plaque volume using a 64 slice spiral CT at 76 weeks;   Change from baseline in blood lipids at 26 weeks;   Change from baseline in hsCRP at 26 weeks;   Change from baseline in Carotid intima-media thickness at 76 weeks;   Number of participants with adverse events and abnormal laboratory safety markers.;   Change from baseline in blood lipids at 52 weeks;   Change from baseline in blood lipids at 76 weeks;   Change from baseline in hsCRP at 52 weeks;   Change from baseline in hsCRP at 76 weeks
20 Not yet recruiting Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels
Conditions: HIV;   Hypercholesterolaemia
Interventions: Drug: Switch ritonavir-boosted PI;   Drug: Continue Ritonavir-boosted PI+Rosuvastatin
Outcome Measures: Percentage change from baseline in total cholesterol at 12 weeks.;   Total cholesterol through week 12;   Safety parameters (HIV viral load, clinical adverse events, serious adverse events, laboratory adverse events, modifications to antiretroviral therapy);   Quality of life (SF-12);   Fasting LDL cholesterol (estimated with Friedewald equation unless triglycerides >400mg/dL, in which case LDL-C would be measured directly), HDL cholesterol, total : HDL cholesterol ratio, LDL particles sizes, triglycerides;   Fasting glucose and insulin.;   Framingham cardiovascular risk score.;   D:A:D 5-year estimated risk calculator.

These studies may lead to new treatments and are adding insight into Rosuvastatin etiology and treatment.

A major focus of Rosuvastatin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Rosuvastatin